Explore recent issues of Contract Pharma covering key industry trends.
Read the full digital version of our magazine online.
Stay informed! Subscribe to Contract Pharma for industry news and analysis.
Get the latest updates and breaking news from the pharmaceutical and biopharmaceutical industry.
Discover the newest partnerships and collaborations within the pharma sector.
Keep track of key executive moves and promotions in the pharma and biopharma industry.
Updates on the latest clinical trials and regulatory filings.
Stay informed with the latest financial reports and updates in the pharma industry.
Expert Q&A sessions addressing crucial topics in the pharmaceutical and biopharmaceutical world.
In-depth articles and features covering critical industry developments.
Access exclusive industry insights, interviews, and in-depth analysis.
Insights and analysis from industry experts on current pharma issues.
A one-on-one video interview between our editorial teams and industry leaders.
Listen to expert discussions and interviews in pharma and biopharma.
A detailed look at the leading US players in the global pharmaceutical and BioPharmaceutical industry.
Browse companies involved in pharmaceutical manufacturing and services.
Comprehensive company profiles featuring overviews, key statistics, services, and contact details.
A comprehensive glossary of terms used in the pharmaceutical and biopharmaceutical industry.
Watch in-depth videos featuring industry insights and developments.
Download in-depth eBooks covering various aspects of the pharma industry.
Access detailed whitepapers offering analysis on industry topics.
View and download brochures from companies in the pharmaceutical sector.
Explore content sponsored by industry leaders, providing valuable insights.
Stay updated with the latest press releases from pharma and biopharma companies.
Explore top companies showcasing innovative pharma solutions.
Meet the leaders driving innovation and collaboration.
Engage with sessions and panels on pharma’s key trends.
Hear from experts shaping the pharmaceutical industry.
Join online webinars discussing critical industry topics and trends.
A comprehensive calendar of key industry events around the globe.
Live coverage and updates from major pharma and biopharma shows.
Find advertising opportunities to reach your target audience with Contract Pharma.
Review the editorial standards and guidelines for content published on our site.
Understand how Contract Pharma handles your personal data.
View the terms and conditions for using the Contract Pharma website.
What are you searching for?
Will more than double current capacity at three German sites
September 30, 2015
By: Kristin Brooks
Managing Editor, Contract Pharma
Vetter is investing approximately €300 million to expand and upgrade its manufacturing facilities during the next five years. The company is preparing for future needs and requirements driven by a changing healthcare market that is affected by issues such as more complex molecules, smaller batch sizes, and increasing regulatory requirements. The first of the facility expansions are underway at several German locations including its ‘Ravensburg Vetter West’ center for visual inspection and logistics. The facility expansion, which will more than double current capacity, is completed scheduled to become fully operational in 2017. Also, the Ravensburg Vetter South production site and the Ravensburg Schuetzenstrasse facility have been designated for significant expansion, where initial construction activities began in 2013. All three sites will have additional capacities for drug product manufacturing and logistic services. A central technology element will be implemented with an in-house made improved restricted access barrier system (RABS) concept aimed at increasing operational excellence in aseptic manufacturing. RABS achieves the sterility assurance level (SAL) required by regulatory authorities, and allows for rapid product change-over coupled with high safety. To better meet future industry trends in quality, safety and flexibility, a corporate project team has evolved this ‘Improved RABS concept’ by combining the advantages of isolator and RABS technology. This approach, according to the company, results in a uniquely fast, 3-hour cycle and fully automated decontamination of the cleanroom using hydrogen peroxide (H2O2), with an extremely high level of process innovation. Following a successful pilot project, the company will now implement this decontamination concept in all of its cleanrooms within the next few years. “We are continuously monitoring and reacting to a changing marketplace and are pleased that we are in the position to be able to make these strategic investments to further develop our sites and meet these challenges. Individually and collectively, they will help us keep pace with the market and allow us to continue to build a successful future for Vetter and our customers,” said Vetter managing director Peter Soelkner.
Enter your account email.
A verification code was sent to your email, Enter the 6-digit code sent to your mail.
Didn't get the code? Check your spam folder or resend code
Set a new password for signing in and accessing your data.
Your Password has been Updated !